trem 1

Lqvtdsglyrcviyhpp TFA 是一种由17个氨基酸组成的多肽，是可穿透血脑屏障的触发受体1 (TREM-1) 抑制剂，具有潜在的抗癌活性，可用于研究皮肤癌和胰腺癌。

TREM-1 inhibitory peptide M3为一种配体依赖的TREM-1拮抗剂。该化合物能够有效抑制全身及肺部促炎细胞因子与趋化因子的产生，有助于缓解急性肺损伤。

TREM-1 inhibitory peptide GF9 (Human TREM-1(213-221)) 为一种九肽，不依赖配体而发挥作用，能有效缓解类风湿性关节炎 (RA) 所引起的过度炎症。

TREM2 agonist-1 (I-246) 是一种髓系细胞触发受体 2 (triggering receptor expressed on myeloid cells-2,TREM2) 激动剂 (EC50: 3.0 μM-100 μM)。该化合物的粉末形式不稳定，建议选择其他盐形式产品。

TREM2-IN-1 (OPA) 是一种铂类 TREM2 抑制剂，具有抗癌抗肿瘤活性，通过阻止 DNA 复制和抑制髓样细胞 2 （TREM2） 上表达的触发受体发挥作用。TREM2-IN-1 抑制巨噬细胞上 TREM2 的免疫调节活性，通过减少 CD206 和 CX 的数量来阻止携带 MC38 结直肠肿瘤的小鼠模型的肿瘤生长+3CR1 免疫抑制性巨噬细胞。

Nangibotide为TREM-1受体抑制剂，具有调节先天免疫反应的作用。在啮齿动物心肌缺血再灌注模型中，Nangibotide能有效减轻全身及原位的炎症反应。

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.

Nangibotide TFA为TREM-1受体抑制剂，调控先天免疫反应。该化合物能降低啮齿动物心肌缺血再灌注模型的系统性及局部炎症。

LQVTDSGLYRCVIYHPP（LP17）是一种多肽和TREM-1(Triggering Receptor Expressed on Myeloid cells 1)抑制剂，序列来源于小鼠和人类TREM-1和TLT-1胞外结构域之间的高度保守序列，通过类似于诱饵受体的机制抑制肌动蛋白激活TREM-1，具有可穿透大脑屏障的优点，能够减轻神经元损伤和炎症反应。

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).